tradingkey.logo

STAAR Surgical Co

STAA
查看详细走势图
23.350USD
-0.280-1.18%
收盘 12/26, 16:00美东报价延迟15分钟
1.15B总市值
亏损市盈率 TTM

STAAR Surgical Co

23.350
-0.280-1.18%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

-1.18%

5天

-7.12%

1月

-10.30%

6月

+38.74%

今年开始到现在

-3.87%

1年

-5.08%

查看详细走势图

TradingKey STAAR Surgical Co股票评分

单位: USD 更新时间: 2025-12-26

操作建议

STAAR Surgical Co当前公司基本面数据相对非常健康,增长潜力很大。当前估值合理,在医疗设备与耗材行业排名52/207位。机构持股占比非常高,近一月多位分析师给出公司评级为持有。最高目标价24.97。中期看,股价处于下降通道。近一个月,市场表现较差,但基本面评分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

STAAR Surgical Co评分

相关信息

行业排名
52 / 207
全市场排名
154 / 4563
所属行业
医疗设备与耗材

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

分析师目标

根据 9 位分析师
持有
评级
24.969
目标均价
+6.07%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

STAAR Surgical Co亮点

亮点风险
STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. The Company markets and sells its ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. Its EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The Company's newest offering, EVO Viva, has an extended depth of focus (EDoF) optic, which is designed to treat myopia with presbyopia (age-related loss of ability to focus). It also market and sell an ICL lens to treat hyperopia (farsightedness), called Visian ICL. It makes its ICL product offerings available in multiple models, powers and lengths, including some with toric ICL (TICL) versions to correct for astigmatism (blurred vision). The Company’s principal products are ICLs used in refractive surgery, including its EVO family of lenses.
业绩转亏
公司业绩转亏,最新年度亏损美元
估值低估
公司最新PE估值-11.96,处于3年历史低位
机构减仓
最新机构持股49.83M股,环比减少23.09%
先锋集团持仓
明星投资者先锋集团持仓,最新持仓市值4.26M
活跃度增加
近期活跃度增加,过去20天平均换手率2.61

STAAR Surgical Co新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

STAAR Surgical Co简介

STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. The Company markets and sells its ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. Its EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The Company's newest offering, EVO Viva, has an extended depth of focus (EDoF) optic, which is designed to treat myopia with presbyopia (age-related loss of ability to focus). It also market and sell an ICL lens to treat hyperopia (farsightedness), called Visian ICL. It makes its ICL product offerings available in multiple models, powers and lengths, including some with toric ICL (TICL) versions to correct for astigmatism (blurred vision). The Company’s principal products are ICLs used in refractive surgery, including its EVO family of lenses.
公司代码STAA
公司STAAR Surgical Co
CEOFarrell (Stephen C)
网址https://www.staar.com/

常见问题

STAAR Surgical Co(STAA)的当前股价是多少?

STAAR Surgical Co(STAA)的当前股价是 23.350。

STAAR Surgical Co的股票代码是什么?

STAAR Surgical Co的股票代码是STAA。

STAAR Surgical Co股票的52周最高点是多少?

STAAR Surgical Co股票的52周最高点是30.810。

STAAR Surgical Co股票的52周最低点是多少?

STAAR Surgical Co股票的52周最低点是13.500。

STAAR Surgical Co的市值是多少?

STAAR Surgical Co的市值是1.15B。

STAAR Surgical Co的净利润是多少?

STAAR Surgical Co的净利润为-20.21M。

现在STAAR Surgical Co(STAA)的股票是买入、持有还是卖出?

根据分析师评级,STAAR Surgical Co(STAA)的总体评级为持有,目标价格为24.969。

STAAR Surgical Co(STAA)股票的每股收益(EPS TTM)是多少

STAAR Surgical Co(STAA)股票的每股收益(EPS TTM)是-1.952。
KeyAI